We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients with Type 2 Diabetes.
- Authors
Mayerson, Adam B.; Hundal, Ripudaman S.; Dufour, Sylvie; Lebon, Vincent; Befroy, Douglas; Cline, Gary W.; Enocksson, Staffan; Inzucchi, Silvio E.; Shulman, Gerald I.; Petersen, Kitt F.
- Abstract
We examined the effect of three months of rosiglitazone treatment (4 mg b.i.d.) on whole-body insulin sensitivity and in vivo peripheral adipocyte insulin sensitivity as assessed by glycerol release in microdialysis from subcutaneous fat during a two-step (20 and 120 mU · m[sup -2] · min[sup -1]) hyperinsulinemic-euglycemic clamp in nine type 2 diabetic subjects. In addition, the effects of rosiglitazone on liver and muscle triglyceride content were assessed by [sup 1]H-nuclear magnetic resonance spectroscopy. Rosiglitazone treatment resulted in a 68% (P < 0.002) and a 20% (P < 0.016) improvement in insulin-stimulated glucose metabolism during the low- and high- dosage-insulin clamps, respectively, which was associated with ~40% reductions in plasma fatty acid concentration (P < 0.05) and hepatic triglyceride content (P < 0.05). These changes were associated with a 39% increase in extramyocellular lipid content (P < 0.05) and a 52% increase in the sensitivity of peripheral adipocytes to the inhibitory effects of insulin on lipolysis (P = 0.04). In conclusion, these results support the hypothesis that thiazolidinediones enhance insulin sensitivity in patients with type 2 diabetes by promoting increased insulin sensitivity in peripheral adipocytes, which results in lower plasma fatty acid concentrations and a redistribution of intracellular lipid from insulin responsive organs into peripheral adipocytes.
- Subjects
PEOPLE with diabetes; TRIGLYCERIDES
- Publication
Diabetes, 2002, Vol 51, Issue 3, p799
- ISSN
0012-1797
- Publication type
Article
- DOI
10.2337/diabetes.51.3.797